Most phosphaturic substance in human body
Reading File
Searching the Web
most potent phosphaturic substance human body FGF-23 PTH
Finding Sources
Reading File
Reading File
FGF-23 - The Most Phosphaturic Substance in the Human Body
FGF-23 (Fibroblast Growth Factor 23) is the most potent phosphaturic substance in the human body. It is also called a "phosphatonin" - a term coined by Econs and Drezner for factors that lower blood phosphorus levels.
Key Facts
| Feature | Detail |
|---|---|
| Structure | 251-amino acid peptide, 26 kDa; gene on chromosome 12p13.3 |
| Source | Osteocytes and osteoblasts in bone (primarily) |
| Co-receptor required | α-Klotho (essential for FGF-23 signaling) |
| Receptor | FGFR1c (primarily), FGFR4 (lesser degree) |
Mechanism of Action
FGF-23 acts on the kidney via Klotho-FGF receptor (FGFR1c) complexes and produces two major effects:
-
Phosphaturic effect: Causes endocytosis and downregulation of NaPi-IIa (NPT2A) and NaPi-IIc (NPT2C) sodium-phosphate cotransporters in the proximal tubule → decreased phosphate reabsorption → phosphaturia
-
Anti-vitamin D effect: Suppresses renal 1α-hydroxylase (CYP27B1) and upregulates 24-hydroxylase → decreased 1,25(OH)₂D (calcitriol) production → less GI phosphate absorption
This two-pronged action makes FGF-23 the dominant regulator of phosphate homeostasis.
Comparison with PTH
While PTH is also phosphaturic (it downregulates NPT2A/2C via NHERF-1), FGF-23 and PTH differ importantly:
| FGF-23 | PTH | |
|---|---|---|
| Phosphaturia | Yes | Yes |
| Effect on 1,25(OH)₂D | Decreases | Increases |
| Net phosphate balance | Lower | Lower |
| Potency as phosphatonin | Primary (most potent) | Secondary |
FGF-23 is considered more potent because it is the master regulator of phosphate homeostasis - it acts on both renal reabsorption AND intestinal absorption (via vitamin D suppression). PTH's phosphaturic action can even develop partial resistance in the absence of FGF-23 signaling.
Regulation of FGF-23 Secretion
FGF-23 is stimulated by:
- High serum phosphate
- 1,25(OH)₂D (calcitriol)
- PTH
- Iron deficiency (via HIF-1α)
- Cleaved/soluble Klotho
FGF-23 is suppressed by:
- Dietary phosphate restriction
- Calcium deficiency
- DMP-1 (dentin matrix protein-1) and PHEX - local bone-derived negative regulators
Clinical Relevance
Excess FGF-23 causes phosphate-wasting disorders:
- X-linked hypophosphatemia (XLH) - PHEX mutations lead to excess FGF-23
- Autosomal dominant hypophosphatemic rickets (ADHR) - gain-of-function FGF-23 mutations resist cleavage
- Tumor-induced osteomalacia (TIO) - phosphaturic mesenchymal tumors secrete FGF-23
- CKD-MBD - elevated FGF-23 rises earliest in CKD (even before serum phosphate or PTH rise)
Deficient FGF-23 causes hyperphosphatemia (as seen in advanced CKD when FGF-23 response is overwhelmed).
Sources: Tietz Textbook of Laboratory Medicine, 7th Ed. | Goodman & Gilman's Pharmacological Basis of Therapeutics | FGF23 and Phosphate Wasting Disorders (Nature/Bone Research)
This is a shared conversation. Sign in to Orris to start your own chat.